Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Nexstim

11.45 EUR

-0.87 %

5,622 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-0.87 %
-9.49 %
-19.37 %
-19.08 %
-21.03 %
+43.12 %
+200.52 %
+44.79 %
-98.11 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
82.59M EUR
Turnover
40.32K EUR
P/E (adj.) (25e)
65.5
EV/EBIT (adj.) (25e)
59.94
P/B (25e)
16.29
EV/S (25e)
7.06
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.00 EUR
Updated
2026-01-04
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-01-05

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

30/3
2026

General meeting '26

14/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types
Nexstim navigates its way to the United Arab Emirates
Analyst Comment16 hours ago by
Antti Siltanen

Nexstim navigates its way to the United Arab Emirates

The marketing authorization for the NBS 6 system in the United Arab Emirates opens up a new market and supports our estimates for future growth.

Nexstim
Press releaseyesterday

Nexstim Receives Clearance for its NBS 6 Diagnostics System in UAE

Nexstim
Press release2/2/2026, 7:00 AM

Nexstim Receives System Order from Distributor in India

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release1/30/2026, 8:00 AM

Nexstim Plc: Proposals of the Shareholders’ Nomination Committee to the Annual General Meeting

Nexstim
Press release1/5/2026, 7:00 AM

Nexstim Receives System Order from Distributor in Middle East

Nexstim
Nexstim: A solid end to a record year
Research1/5/2026, 8:27 AM by
Antti Siltanen

Nexstim: A solid end to a record year

In Nexstim's system sales, the summer of 2025 was particularly busy and helped the company achieve a full-year sales record in terms of units.

Nexstim
Regulatory press release12/30/2025, 8:00 AM

Nexstim Plc’s Financial Information and Annual General Meeting in 2026

Nexstim
Press release12/30/2025, 7:00 AM

US Customer Orders Two Nexstim NBS 6 Therapy Systems

Nexstim
Press release12/29/2025, 7:00 AM

Nexstim Receives NBS 6 System Order from New US Customer

Nexstim
Nexstim's exclusivity agreement with Sinaptica proceeds with revised payment structure
Analyst Comment12/29/2025, 8:12 AM by
Antti Luiro

Nexstim's exclusivity agreement with Sinaptica proceeds with revised payment structure

The agreement ensures continued cooperation until 2026, but the payment arrangement has shifted from an original cash-based plan to one weighted toward convertible debt.

Nexstim
Press release12/23/2025, 9:30 AM

Distributor Orders Nexstim NBS 6 System

Nexstim
Regulatory press release12/23/2025, 7:00 AM

Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc.

Nexstim
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Press release12/16/2025, 7:00 AM

Finnish Private Clinic Group Orders Two Nexstim NBS 6 Systems

Nexstim
Press release12/15/2025, 7:00 AM

Nexstim Receives Therapy System Order from US Customer

Nexstim
Press release12/3/2025, 7:59 AM

BioStock: Nexstim: från Helsingfors till en global hjärnrevolution

Nexstim
Press release12/3/2025, 7:59 AM

BioStock: Nexstim: from Helsinki to a global brain revolution

Nexstim
Press release11/20/2025, 7:00 AM

Nexstim Receives NBS 6 System Order from New Research Customer

Nexstim
Press release11/19/2025, 7:28 AM

BioStock: Video från Nexstims presentation vid BioStock Life Science Summit 2025

Nexstim
Press release11/19/2025, 7:28 AM

BioStock: Video from Nexstim's presentation at BioStock Life Science Summit 2025

Nexstim
Forum discussions
nexstim.com Nexstim - Press-release Nyt voidaan toimitella NBS6:sta arabeille.
yesterday
by Mark_Renton
25
Looking through rose-tinted glasses: I wonder if a backlog for NBS6 sales has already built up in the UAE, which Brainlab can now start clearing? In my previous job, I dealt with customers from that region to some extent, and there is a very strong phenomenon where you have to get...
15 hours ago
by Mark_Renton
23
Sinaptica’s Mariashi accepting the MedTech award.
2/15/2026, 8:23 AM
by Jatast
17
Here are Antti’s comments on how Nexstim received marketing authorization for its latest generation NBS 6 diagnostic equipment in the United Arab Emirates. Inderes Nexstim navigoi tiensä Arabiemiirikuntiin - Inderes NBS 6 -laitteiston myyntilupa Arabiemiirikunnissa avaa uuden markkinan...
16 hours ago
by Sijoittaja-alokas
15
Here is a link to the right spot
yesterday
by Kyhnykeisari
14
In the post-pitch Q&A, it was mentioned that with that 25 million, Phase 3 can be completed and the product further developed, but commercializing the product will then require more money. Then it’s a separate question what Sinaptica’s plans are after a successful Phase 3. One option...
7 hours ago
by Kyhnykeisari
10
Now that AI is disrupting almost all industries across the board, the question arises as to how this will affect Nexstim’s business. I’ve been mulling over various scenarios, but I can’t easily come up with any dramatic angle where AI would reduce the need for Nexstim’s devices. ...
2/13/2026, 9:00 AM
by Mark_Renton
10
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.